The biomaterials market is driven by a number of factors such as superior properties of biomaterials, increasing funds/aids by the government for research purposes, increasing wound healing therapies & plastic surgeries, increasing aging/geriatric population, rise in prevalence of cardiovascular diseases, increasing awareness of regenerative medicine, increasing orthopedic disorders, and growing demand for implantable devices.
New York, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biomaterials Market - A Global and Regional Analysis: Focus on Applications, Product Types, and Countries - Analysis and Forecast, 2021-2031" - https://www.reportlinker.com/p06169596/?utm_source=GNW However, biocompatibility issues, stringent safety regulations, and limitations of biomaterial-based products are hampering the growth of the biomaterials market. Increasing obesity, the introduction of biomaterials in cancer research, and increasing patient awareness and improved lifestyle in growing economies such as India, China, and South Korea are expected to create opportunities in the biomaterials market. Market Segmentation Biomaterials Market by Application Among different biomaterials applications, cardiovascular dominates the market and is expected to be the largest application during the forecast period.The growing use of biomaterials in the cardiovascular application segment is majorly subjected to its biocompatibility as biomaterials come in contact with blood, vascular endothelial cells, fibroblasts, and myocardium, as well as a number of other cells and a cellular matrix material. Biomaterials that are used in the cardiovascular system include materials such as metals and polymers. The use of biomaterials in the cardiovascular system can be classified as temporary internal, temporary external, and permanent internal devices. Biomaterials Market by Product Among different biomaterials product type metal-based biomaterials dominates the market and is expected to be the largest product type during the forecast period.The dominance of metal-based biomaterials is attributed to wide use in the applications of biomaterials such as cardiovascular, orthopedic, ophthalmology, dental. From simple wires, rods, pins, screws to fracture fixation plates and total joint prostheses (artificial joints) for hips, knees, shoulders, and ankles, metals are used in all applications, including maxillofacial surgery, cardiovascular surgery, and dental materials, etc. The metal-based biomaterials include stainless steel, commercially pure titanium and titanium alloys, cobalt and chromium alloys, gold, silver, magnesium, and nitinol. Biomaterials Market by Region The demand for biomaterials varies according to various regions. The biomaterials market holds a prominent share in various countries of North America, Asia-Pacific and Japan, Europe, the U.K., China, and Rest-of-the-World, among which North America is expected to be the largest region for the global biomaterials market during the forecast period. Industrial advancements, extensive investments for dedicated R&D facilities, and the development of different application products that require biomaterials are some of the major drivers that are currently propelling the growth of the North America biomaterials market. Additionally, due to the wide-scale production of biomaterials as well as technological advancements pertaining to the technology, the global market for biomaterials is expected to grow at a steady rate. Key Market Players and Competition Synopsis BASF SE, Carpenter Technology Corporation, Celanese Corporation, Collagen Solutions Plc, Corbion N.V., Covestro AG, DSM, Evonik Industries, Zimmer Biomet, Wright Medical Group N.V., Mitsubishi Chemical Holdings Corporation, Riton Biomaterial Co., Ltd., Berkeley Advanced Biomaterials Inc., BBS-Bioactive Bone Substitutes Oyj, Bioretec Ltd. The companies that are profiled in the report have been selected based on a selective pool of players, primarily Tier-1 (holding 50-60% of the market) and mid-segment players (comprising 30-40% share), and small and emerging companies (holding the balance 10-20% share), based on various factors such as product portfolios, annual revenues, market penetrations, research, and development initiatives, along with a domestic and international presence in the biomaterials industry. Countries Covered • North America • U.S. • Canada • Mexico • Europe • Germany • Italy • France • Spain • Russia • Rest-of-Europe • U.K. • China • Asia-Pacific and Japan • Japan • India • South Korea • Rest-of-Asia Pacific and Japan • Rest-of-the-World (RoW) • South America • Middle East and Africa Read the full report: https://www.reportlinker.com/p06169596/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________
Every investor in NIO Inc. ( NYSE:NIO ) should be aware of the most powerful shareholder groups. Generally speaking, as...
The drugmaker says its acoramidis trial for ATTR-CM treatment didn't meet primary endpoints, sending the stock plummeting.
As we get ready to turn the page on 2021, I can't help but note how we've witnessed a pretty substantial market bifurcation in stocks over the past couple of quarters. Below are four stocks that I believe are likely to find their way into my portfolio in 2022. A year ago, I was completely against electric vehicle (EV) manufacturer Nio (NYSE: NIO).
Sorrento Therapeutics Inc. announced Monday a contract for the sale and distribution of up to 10 million its Covistix rapid COVID-19 virus detection tests in Mexico. That follows a previously announced deal for up to 5 million Covistix tests in Mexico, bringing the total number of tests to 15 million. The biopharmaceutical company said independent clinical testing of Covistix by a Mexico-based national institute showed a "very high sensitivity" of around 90% in an "all-comers" population, includ
Web 3.0 is widely considered to be the next frontier of internet technology, making the metaverse a golden macrotrend for retail investors. The metaverse refers to an easily scalable real-time virtual reality or mixed reality world, comprising several interoperable, immersive, and interactive 3D environments. The metaverse is also expected to maintain all relevant information about payments, identity, and history across user sessions.
Investing in stocks can be a risky endeavor. Buying a stock does not guarantee an investor a return on that investment. For that matter, it does not even guarantee an investor a return of their initial investment.
It's been a dreadful year for Citigroup (NYSE: C) in terms of stock price performance, with shares of the megabank down about 1% this year. The KBW Nasdaq Bank Index, which tracks large bank stocks, is up nearly 35% this year, showing just how much Citigroup has lagged the broader sector. Trading at beaten-down levels, can Citigroup turn it around in 2022?
The company, which is sparing its executives from the cut, says it brings benefits in line with what other firms offer. One retiree: ‘If there isn’t a legal obligation, there certainly is a moral obligation.’
With a market cap of $1.3 billion and trailing revenue of 47.2 million Canadian dollars ($36.5 million), Sundial is neither profitable nor rapidly growing. Let's consider one argument in favor of buying Sundial stock and one argument against it to determine if it's a good choice to add to your portfolio. Alex Carchidi: Though it's a risky stock to be sure, Sundial's turnaround story is on the verge of bearing fruit.
When you leave a job, and an IRA rollover is only one way to preserve the money’s tax-deferred status, and it's not always the best.
Shares of BridgeBio Pharma Inc. plummeted 66.2% in premarket trading Monday, after the drug maker said a Phase 3 study of its acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) failed to meet its primary endpoint at Month 12. The company said the decline observed in both arms of the study was similar to expected functional decline in healthy elderly adults, and were also "substantially less" than declines observed in previous untreated arms reviewed
These last few weeks of 2021 have seen increased market volatility. Along with Omicron fears, the market fluctuations have come just as Wall Street is digesting the fact of a new Fed policy in the New Year, including the tightening up of monetary policy and at least one, probably more, interest rate hikes. The Fed’s easy money has been supportive for the better part of the past decade or more, and investors are rightly wondering how the market will adapt. Looking ahead, Wedbush’s Daniel Ives is
Stocks rose ahead of the traditional Santa Claus rally. Tesla is still rising. AMD leads stocks flashing buy signals.
If you have $100 at the ready not needed for bills or emergencies and a brokerage that allows fractional share purchases, you have enough to buy into the following pair of no-brainer stocks right now. Palantir Technologies (NYSE: PLTR) is the Liam Neeson of data analytics stocks: It has a very particular set of skills that were acquired over a very long career. The U.S. military is also a prime customer, using Palantir's technology to coordinate millions of troops around the world.
The dividends for such stocks are pretty much their only attraction. On the other hand, you can find dividend stocks that are anything but boring and stodgy. Here are three dividend stocks that soared more than 50% in 2021 and are still great buys.
ClearBridge Investments, an investment management firm, published its “Small Cap Value Strategy” third quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Small Cap Value Strategy outperformed the Russell 2000 Value Index, the Strategy’s benchmark, during the third quarter of 2021. You can take a look at the fund’s […]
'Rich Dad Poor Dad' is as bearish as ever.
What were you expecting? A six-figure allowance?
Public DeFi applications are absent on Cardano in December 2021, but that’s not deterring Hoskinson from visualizing widespread activity on the network in 2022.
China's BYD will look to top the 100,000 mark, after setting a sixth monthly EV sales record. Nio stock rose.